47results about How to "Delaying occurrence" patented technology

The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof which are specific, potent and safe inhibitors of the Ca.sup.2+-activated potassium channel (Gardos channel) of erythrocytes. The compounds can be used as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation.

Provided is a display apparatus having a structure capable of realizing reduction in thickness and border width.

A display apparatus having a liquid-crystal panel prepared by enclosing a liquid-crystal material between a pair of glass substrates opposing to each other, a transparent plate opposed to the liquid-crystal panel, and an optical sheet arranged between the liquid-crystal panel and the transparent plate, and having a face smaller than the liquid-crystal panel, wherein the transparent plate is a glass plate having a wide surface of substantially a same shape as a wide surface of each of the glass substrate, and the display apparatus further comprises a frame body arranged between the liquid-crystal panel and the transparent plate, the frame body surrounding an outer periphery of the optical sheet, the frame body being thicker than the optical sheet.

While comprising filled minor compartments being filled with an inclusion in which a liquid makes the major component, and vacant minor compartments being filled with the air, at least one of the vacant minor compartments adjoins the filled minor compartments, and a fragile section is formed in at least one of ribs that demarcate the filled minor compartments and the adjoining vacant minor compartments. After the fragile section has fractured, shock energy can be absorbed furthermore by means of circulation resistance to the inclusion that flows from the filled minor compartments to the vacant minor compartments.

A nonaqueous electrolyte secondary battery including a negative electrode containing a graphite material as the negative active material, a positive electrode containing lithium cobalt oxide as a main component of the positive active material and a nonaqueous electrolyte solution, the battery being characterized in that the lithium cobalt oxide contains a group IVA element and a group IIA element of the periodic table, the nonaqueous electrolyte solution contains 0.2-1.5% by weight of a sulfonyl-containing compound and preferably further contains 0.5-4% by weight of vinylene carbonate.

The invention provides a method for fabricating wick microstructures in heat pipes, comprising the following steps: providing a flat plate and a mold with several molding holes; filling a dry powder material in the several molding holes and putting the mold to cover the flat plate so as to form an object to be sintered; sintering the object; and removing the mold to form a flat plate with wick microstructures. The wick microstructures are arranged on the flat plate in a form of microgrooves, microcylinders or any combination of them. The flat plate with wick microstructures is further processed to form a heat pipe with a characteristic shape and having two kinds of wick microstructures such that the heat transferred by the heat pipe is increased and the occurrence of dry out of the heat pipe is delayed.

The present invention provides substituted 11-phenyl-dibenzazepine compounds that are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.

A spark plug comprising a cylindrical portion which projects into a combustion chamber from an inner wall face of an engine head when the spark plug is fixed to the engine head, wherein the cylindrical portion has one or more ventilating portion comprised of a through hole or a notch in an outer circumferential face thereof. An igniting portion projecting into the combustion chamber improves ignitability. Further, because an air-fuel mixture fed from an inlet of the internal combustion engine flows to inside of the cylindrical portion through the ventilating portion, heat of an insulator is taken away and cooled down, whereby an occurrence of pre-ignition is prevented.

A tire has cap rubber that forms a contact patch. The cap rubber has a plurality of lugs. A shoulder lug, which among the plurality of lugs is that which is located outwardmost in a tire width direction, has a narrow groove that extends in the tire circumferential direction and that partitions the shoulder lug into a main lug portion toward the interior in the tire width direction, and a sacrificial lug portion toward the exterior in the tire width direction; and low-modulus rubber, for which stress at a given elongation is lower than that of the cap rubber, is arranged at a corner where the contact patch at the main lug portion and a groove side face toward the interior in the tire width direction which forms the narrow groove intersect.

Disclosed is an internal combustion engine component (1) comprising at least one area (4) that is subject to a greater thermal load then another area (5) during operation of the internal combustion engine. The area (4) that is subjected to a greater thermal load is provided with a lower heat expansion coefficient (α₂) then the area (5) which is subject to a lower thermal load.

The present invention relates to a medium for direct differentiation of embryonic stem cell-derived mesenchymal stem cells, a method of preparing mesenchymal stem cells by using same, mesenchymal stem cells prepared thereby, and a cell therapy product comprising the same mesenchymal stem cells. In a medium composition and a method according to an embodiment, mesenchymal stem cells may be prepared at high yield within a short period of time. In addition, the method is simple in preparation procedure because of the absence of an embryoid body formation step and allows homogeneous cells to be prepared, thus advantageously providing a cell therapy product within a reduce period of time, compared to conventional methods.

The present invention relates to a method and composition for treating melanoma, aggressive/invasive melanoma, metastatic melanoma or melanoma resistant. More particularly, inventors have shown that high expression of PTX3 correlates with melanoma invasiveness and with a poorer survival rate in metastatic melanoma patients. PTX3 knockdown inhibited melanoma cell migration, invasion, lung metastasis, and NFκB signaling pathway. An addition of melanoma-derived or recombinant PTX3, or overexpression of PTX3 enhanced motility of low migratory cells. Finally, they found that TLR4 and MYD88 knockdown or targeting inhibited PTX3-induced melanoma cell migration, suggesting that PTX3 functions through a TLR4/NFκB-dependent pathway. Accordingly, the invention relates to a method for predicting the survival time of a subject suffering from melanoma, aggressive/invasive melanoma, metastatic melanoma or melanoma resistant by quantifying the expression level of PTX3 in a biological sample and to a method of treating melanoma, aggressive/invasive melanoma, metastatic melanoma or melanoma resistant by using the inhibitors of PTX3.

The present invention relates to a combination therapy for tumours comprising the administration of an epoxytigliane compound and an immune checkpoint inhibitor. In particular embodiments, there is a method of treating a tumour and/or treating or preventing one or more bystander tumours with the therapy. Pharmaceutical compositions and kits containing epoxytigliane compounds and immune checkpoint inhibitors are also described.